ABIVAX - Articles and news items

First ever evidence of treatment-induced reduction in HIV reservoirs

Industry news / 4 May 2017 / Niamh Marriott, Junior Editor

Abivax’s lead therapeutic candidate ABX464 demonstrated the first reduction in HIV reservoirs ever observed in chronically infected HIV patients…


Mechanism of action of First-in-class anti-HIV drug, ABX464, published

Industry news / 13 April 2015 / Victoria White

ABIVAX, a biotechnology company developing first-in-class anti-viral drugs and vaccines, has announced publication of the mechanism of action of ABX464…

Abivax logo

ABIVAX signs agreement with the Finlay Institute to commercialise meningococcal and typhoid vaccines in Asia and Latin America

Industry news / 13 November 2014 / ABIVAX

ABIVAX, a leading European, clinical stage biopharmaceutical company developing and commercializing anti-viral compounds and human vaccines, announced that it has signed an agreement with The Finlay Institute, Havana, Cuba…

Abivax logo

ABIVAX strengthens Executive Management team with senior appointments

Industry news / 4 November 2014 / ABIVAX

ABIVAX has appointed Karl Birthistle, M.D., and Daniel Kenny to its Executive Management team as VP of Global Regulatory Affairs and Chief Commercial Officer & VP of Business Development, respectively…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...